

Connecting via Winsock to STN


Welcome to STN International! Enter x:x

FILE 'HOME' ENTERED AT 14:11:10 ON 10 SEP 2008

=> file req

⇒

Uploading C:\Program Files\Stnexp\Queries\10577531.str



chain nodes :

17 18 19 20 21 23 26 27 28 29 30

ring nodes :

1 2 3 4

chain

chain bonds

29-30

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 11-12 11-16 12-13 13-14
 14-15 15-16 22-24 22-25 24-25

exact/norm bonds :

6-29 10-17 11-17 14-19 19-20 20-21 20-23 21-22 22-24 22-25 24-25 26-27

26-28 29-30

exact bonds :

5-26 15-18

10/553937

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:Atom 23:CLASS 24:Atom 25:Atom 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

L3 35 SEA SSS FUL L1

=> file ca

=> s 13
 L4 22 L3

=> d ibib abs hitstr 1-22


L4 ANSWER 1 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 149:239320 CA
 TITLE: Composition for treatment of undifferentiated-type of
 gastric cancer
 INVENTOR(S): Yamamoto, Yuji
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 221pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008093855	A1	20080807	WO 2008-JP51697	20080128
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2007-887006P P 20070129
 AB Disclosed are: a therapeutic agent, a kit and a treatment method for
 undifferentiated-type of gastric cancer; and a pharmaceutical composition, a
 kit and a treatment method which are more effective on a living body
 having at least one cell selected from the group consisting of a cell
 over-expressing FGFR2 and a cell expressing a FGFR2 mutant. A combination
 of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is
 more effective on undifferentiated-type of gastric cancer. The
 combination of a FGFR2 inhibitor and a therapeutic substance for gastric
 cancer is more effective on a living body having at least one cell
 selected from the group consisting of a cell over-expressing FGFR2 and a
 cell expressing a FGFR2 mutant. For example, the synergistic effect of
 combination of 4-(3-chloro-4-[cyclopropylaminocarbonyl)aminophenoxy]-7-
 methoxy-6-quinolinecarboxamide and irinotecan hydrochloride in HSC-30
 human gastric carcinoma cell-bearing mice was examined
 IT 417716-92-8, 4-(3-Chloro-4-[cyclopropylaminocarbonyl)aminophenoxy]-
 7-methoxy-6-quinolinecarboxamide 857890-39-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (composition for treatment of undifferentiated-type of gastric cancer
 containing
 quinoline derivs. in combination with antitumor agent or FGFR2
 inhibitor)

RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




RN 857890-39-2 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1


CRN 417716-92-8

CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2
 CMF C H4 O3 S



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 149:167954 CA
 TITLE: Composition for treatment of pancreatic cancer
 INVENTOR(S): Yamamoto, Yuji
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 126pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008088088	A1	20080724	WO 2008-JP51024	20080118
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2007-885733P	P 20070119
			US 2007-887010P	P 20070129

OTHER SOURCE(S): MARPAT 149:167954
 AB Disclosed are a pharmaceutical composition having excellent antitumor activity, and a method for treating a cancer. Specifically, excellent antitumor activity is achieved when 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (A) or an analogous compound thereof, a pharmacol. acceptable salt thereof or a solvate of any of them is used in combination with gemcitabine or erlotinib, a pharmacol. acceptable salt thereof or a solvate of any of them. For example, the effect of combination of a compound A 3 mg/kg and gemcitabine hydrochloride 200 mg/kg on AsPC-1 human pancreatic cancer cell-bearing mice was examined
 IT 417716-92-8, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 417717-05-6,
 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417717-07-8, 4-(3-Chloro-4-


(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide 417717-10-3, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide 417717-15-8, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide 417719-50-7, 4-(3-Chloro-4-(cis-2-fluorocyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 417719-56-3, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide 417719-77-8, 4-(3-Chloro-4-[(cyclopropylamino)carbonyl]amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide 857890-39-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. containing urea derivs. in combination with gemcitabine or erlotinib)


RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417717-05-6 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)



RN 417717-07-8 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 417717-10-3 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)



BN 417717-15-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417719-50-7 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 857890-39-2 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S




REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT.

L4 ANSWER 3 OF 22 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 148:323091 CA
TITLE: Antitumor agent for undifferentiated gastric cancer
INVENTOR(S): Yamamoto, Yuji; Matsushima, Tomohiro; Tsuruoka,
Akihiko; Obaishi, Hiroshi; Nakagawa, Takayuki
PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
SOURCE: PCT Int. Appl., 138pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008026748	A1	20080306	WO 2007-JP67088	20070827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: JP 2006-230816 A 20060828
OTHER SOURCE(S): MARPAT 148:323091

GI




AB A compound represented by the general formula (I), a pharmacol. acceptable salt thereof, or a solvate of the compound or the salt can exert its effect

more effectively on undifferentiated gastric cancer, and can also exerts its effect more effectively on a living body having at least one member selected from the group consisting of a cell over-expressing FGFR2 and a cell expressing mutant FGFR2.

IT 417716-92-8P, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (quinolinylurea analogs as antitumor agents for undifferentiated gastric cancer)

RN 417716-92-8 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



IT 417717-05-6, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417717-07-8
 417717-10-3 417717-15-8, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide 417719-50-7 417719-56-3
 417719-77-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (quinolinylurea analogs as antitumor agents for undifferentiated gastric cancer)


RN 417717-05-6 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)




RN 417717-07-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 417717-10-3 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 417717-15-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417719-50-7 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[([(1R,2S)-2-fluorocyclopropyl]amino)carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 22 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 148:253561 CA

TITLE: E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

AUTHOR(S): Matsui, Junji; Yamamoto, Yuji; Funahashi, Yasuhiro; Tsuruoka, Akihiko; Watanabe, Tatsuo; Wakabayashi, Toshiaki; Uenaka, Toshimitsu; Asada, Makoto

CORPORATE SOURCE: Tsukuba Research Laboratories, Tsukuba, Ibaraki, 300-2635, Japan

SOURCE: International Journal of Cancer (2007), Volume Date 2008, 122(3), 664-671
CODEN: IJCNNA; ISSN: 0020-7136

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB E7080 is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. In this study, we show the inhibitory activity of E7080 against SCF-induced angiogenesis in vitro and tumor growth of SCF-producing human small cell lung carcinoma H146 cells in vivo. E7080 inhibits SCF-driven tube formation of HUVEC, which express SCF receptor, KIT at the IC₅₀ value of 5.2 nM and it was almost identical for VEGF-driven one (IC₅₀ = 5.1 nM). To assess the role of SCF/KIT signaling in tumor angiogenesis, we evaluated the effect of imatinib, a selective KIT kinase inhibitor, on tumor growth of H146 cells in nude mice. Imatinib did not show the potent antitumor activity in vitro (IC₅₀ = 2,200 nM), because H146 cells did not express KIT. However, oral administration of imatinib at 160 mg/kg clearly slowed tumor growth of H146 cells in nude mice, accompanied by decreased microvessel d. Oral administration of E7080 inhibited tumor growth of H146 cells at doses of 30 and 100 mg/kg in a dose-dependent manner and caused tumor regression at 100 mg/kg. While anti-VEGF antibody also slowed tumor growth, it did not cause tumor regression. These results indicate that KIT signaling has a role in tumor angiogenesis of SCF-producing H146 cells, and E7080 causes regression of H146 tumors as a result of antiangiogenic activity mediated

by inhibition of both KIT and VEGF receptor signaling. E7080 may provide therapeutic benefits in the treatment of SCF-producing tumors.


IT 417716-92-8

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(E 7080; E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition)

RN 417716-92-8 CA

CN 6-Quinolinicarboxamide, 4-[3-chloro-4-[[cyclopropylamino]carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 22 CA COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 148:113266 CA

TITLE: Therapeutic agent for liver fibrosis

INVENTOR(S): Yokohama, Hiromitsu; Matsuoka, Toshiyuki

PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan

SOURCE: PCT Int. Appl., 82pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008001956	A1	20080103	WO 2007-JP63525	20070629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,				

TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-817872P P 20060629

OTHER SOURCE(S): MARPAT 148:113266


AB The object is to provide a therapeutic agent for liver fibrosis and a method for treatment of liver fibrosis. 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or an analog thereof can prevent the fibrillation in the liver, and therefore can be used as a therapeutic agent for liver fibrosis or in the method for treatment of liver fibrosis.

IT 417716-92-8, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide 417717-05-6,
 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417717-07-8 417717-10-3
 417717-15-8 417719-50-7 417719-56-3
 417719-77-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide analogs as therapeutic agents for liver fibrosis)


RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417717-05-6 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)



RN 417717-07-8 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 417717-10-3 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 417717-15-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417719-50-7 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 22 CA COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 148:24395 CA

TITLE: Antitumor agent for thyroid cancer containing RET kinase inhibitors

INVENTOR(S): Matsui, Junji

PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan

SOURCE: PCT Int. Appl., 140pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007136103	A1	20071129	WO 2007-JP60560	20070517
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2006-747570P P 20060518

OTHER SOURCE(S): MARPAT 148:24395

AB It is intended to provide a pharmaceutical composition exhibiting an effect more effectively on at least one disease selected from the group consisting of multiple endocrine neoplasia type IIA, multiple endocrine neoplasia type IIB, familial medullary thyroid carcinoma, thyroid cancer, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung's disease, pheochromocytoma, parathyroid hyperplasia and

gastrointestinal mucosal neuroma; and a therapeutic method for the same. A compound 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (I) and an analog thereof can exhibit an effect more effectively on at least one disease selected from the group consisting of multiple endocrine neoplasia type IIA, multiple endocrine neoplasia type IIB, familial medullary thyroid carcinoma, thyroid cancer, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung's disease, pheochromocytoma, parathyroid hyperplasia and gastrointestinal mucosal neuroma. Usage of the RET kinase inhibitor for production of remedy for the diseases listed above, and a pharmaceutical composition containing the

RET

kinase inhibitor for treatment of biol. body including mutant RET protein, and method for prediction of sensitivity to RET kinase inhibitors through intracellular mutant RET protein as an indicator are also disclosed. For example, the inhibitory effect of I on RET kinase in human thyroid carcinoma cells (TT cells) was examined. Also, a coated tablet containing I methanesulfonate was formulated.

IT

417717-07-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-[2-(4-morpholino)ethoxy-6-quinolinecarboxamide; antitumor agent for thyroid cancer containing RET kinase inhibitors)

RN

417717-07-8 CA

CN

6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholiny)ethoxy]- (CA INDEX NAME)



IT


417716-92-8 417717-05-6 417717-10-3,
4-[3-Chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-(2-hydroxyethoxy)-6-quinolinecarboxamide 417717-15-8, 4-[3-Chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-[(2S)-2,3-dihydroxypropyl]oxy-6-quinolinecarboxamide 417719-50-7, 4-[3-Chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide 417719-56-3, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-(2-ethoxyethoxy)-6-quinolinecarboxamide 417719-77-8, 4-[3-Chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-

hydroxy-3-(1-pyrrolidino)propoxy]-6-quinolinecarboxamide
857890-39-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(antitumor agent for thyroid cancer containing RET kinase inhibitors)


RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



RN 417717-05-6 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)



RN 417717-10-3 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)


phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 417717-15-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417719-50-7 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 857890-39-2 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S



L4 ANSWER 7 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 147:235192 CA
 TITLE: Preparation of urea derivatives containing nitrogenous aromatic ring compounds as inhibitors of angiogenesis
 INVENTOR(S): Funahashi, Yasuhiro; Tsuruoka, Akihiko; Matsukura, Masayuki; Haneda, Toru; Fukuda, Yoshio; Kamata, Junichi; Takahashi, Keiko; Matsushima, Tomohiro; Miyazaki, Kazuki; Nomoto, Ken-Ichi; Watanabe, Tatsuo; Obaishi, Hiroshi; Yamaguchi, Atsumi; Suzuki, Sachie; Nakamura, Katsushi; Mimura, Fusayo; Yamamoto, Yuji; Matsui, Junji; Matsui, Kenji; Toshiba, Takako; Suzuki, Yasuyuki; Arimoto, Itaru
 PATENT ASSIGNEE(S): Eisai Co., Ltd, Japan
 SOURCE: U.S., 458pp., Cont.-in-part of Appl. No. PCT/JP01/09221.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7253286	B2	20070807	US 2003-420466	20030418
US 20040053908	A1	20040318		
WO 2002032872	A1	20020425	WO 2001-JP9221	20011019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1506962	A2	20050216	EP 2004-25700	20011019
EP 1506962	A3	20050302		
EP 1506962	B1	20080702		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
EP 1777218	A1	20070425	EP 2006-23078	20011019
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
CN 101024627	A	20070829	CN 2007-10007096	20011019
CN 101029022	A	20070905	CN 2007-10007097	20011019
ES 2282299	T3	20071016	ES 2001-976786	20011019
ZA 2003003567	A	20040810	ZA 2003-3567	20030508
JP 2005272474	A	20051006	JP 2005-124034	20050421


US 20060247259	A1	20061102	US 2005-293785	20051202
US 20060160832	A1	20060720	US 2006-347749	20060203
AU 2006203099	A1	20060810	AU 2006-203099	20060719
AU 2006236039	A1	20061207	AU 2006-236039	20061116
AU 2006236039	B2	20080522		

PRIORITY APPLN. INFO.:

JP 2000-320420	A 20001020
JP 2000-386195	A 20001220
JP 2001-46685	A 20010222
WO 2001-JP9221	A2 20011019
AU 2001-295986	A3 20011019
AU 2001-95986	TO 20011019
CN 2001-819710	A3 20011019
EP 2001-976786	A3 20011019
JP 2002-536056	A3 20011019
US 2003-420466	A3 20030418
US 2005-293785	A1 20051202

OTHER SOURCE(S): MARPAT 147:235192

GI



AB N-aryl or N-heteroarylurea derivs. represented by the general formula Ag-Xg-Yg-Tg1 or salts thereof, or hydrates of both [wherein Ag = (un)substituted C6-14 aryl or 5- to 14-membered heterocyclic group; Xg = single bond, O, S, C1-6 alkylene, SO, SO2, (un)substituted NH; Yg = (un)substituted C6-14 aryl, 5- to 14-membered heterocyclic group, C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl-C1-6 alkyl, 5- to 14-membered heteroaryl-C1-6 alkyl, (CH2)gSO2 (g = 1-8), (CH2)faCH:CH(CH2)fb (fa, fb = 0, 1, 2, 3), etc.; and Tg1 = a group of the general formula -Eg-CO-NRg1(Zg) or Q; wherein Eg = a single bond, (un)substituted NH; Rg1 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 aliphatic hydrocarbyl, etc.; Zg = C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl, etc.; Zg1, Zg2 = (a) a single bond, (b) C1-6 alkylene optionally having ≥ 1 atoms selected from O, S, and N in the middle or the terminus of the chain and optionally substituted with oxo, (c) (un)substituted C2-6 alkenyl] are prepared. These compds. are also inhibitors of vascular endothelial growth factor receptor kinase (VEGFR2 kinase) and are useful as antitumor agents against hemangioma, pancreatic cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, lung cancer, brain tumor, leukemia, or ovarian cancer, as cancer metastasis inhibitors, and for the treatment of retina neovascularization, diabetic retinopathy, atherosclerosis, or inflammatory diseases such as osteoarthritis, rheumatoid arthritis, psoriasis, or delayed hypersensitivity. Thus, to a solution of 334 mg 4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilyl ethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenylamine in 4 mL DMF were added 0.066 mL pyridine and 0.102 mL Ph chlorocarbonate and stirred at room temperature for 2.5 h to give 330 mg N-[4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilyl ethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea which

(260 mg) was hydrogenolyzed over platinum oxide in ethanol overnight to give 160 mg N-[4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea (I). I showed IC₅₀ of 0.02 nM for inhibiting the vascular endothelial growth factor (VEGF)-stimulated sandwich tube formation in vascular endothelial cell.

IT 417717-12-5P 417717-13-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of urea derivs. containing nitrogenous aromatic ring compds. as angiogenesis inhibitors for prevention or treatment of diseases)

RN 417717-12-5 CA

CN 6-Quinolinicarboxamide, 4-[3-chloro-4-[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[[[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417717-13-6 CA

CN 6-Quinolinicarboxamide, 4-[3-chloro-4-[[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.




IT 417716-92-8P 417717-03-4P 417717-05-6P
 417717-06-7P 417717-07-8P 417717-08-9P
 417717-09-0P 417717-10-3P 417717-11-4P
 417717-14-7P 417717-15-8P 417717-16-9P
 417717-17-0P 417717-18-1P 417717-19-2P
 417719-50-7P 417719-56-3P 417719-57-4P
 417719-77-8P 417720-06-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of urea derivs. containing nitrogenous aromatic ring compds. as angiogenesis inhibitors for prevention or treatment of diseases)


RN 417716-92-8 CA

CN 6-Quinolinicarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417717-03-4 CA


CN 6-Quinolinicarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(phenylmethoxy)- (CA INDEX NAME)



RN 417717-05-6 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)




RN 417717-06-7 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)




RN 417717-07-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 417717-08-9 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 417717-09-0 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 417717-10-3 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)




RN 417717-11-4 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p-henoxy]-7-(3-hydroxypropoxy)- (CA INDEX NAME)



RN 417717-14-7 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p-henoxy]-7-[(2R)-2,3-dihydroxypropoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417717-15-8 CA


CN 6-Quinolincarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 417717-16-9 CA

CN 6-Quinolincarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(1,3-dioxolan-2-ylmethoxy)- (CA INDEX NAME)




RN 417717-17-0 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[3-(diethylamino)propoxy]- (CA INDEX NAME)




RN 417717-18-1 CA

CN 1-Piperidinecarboxylic acid, 4-[[[6-(aminocarbonyl)-4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-quinolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 417717-19-2 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




RN 417719-50-7 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[([(1R,2S)-2-fluorocyclopropyl]amino)carbonyl]amino]phenoxy-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 417719-56-3 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-57-4 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(cyclopropylmethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417720-06-0 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-3-(diethylamino)-2-hydroxypropoxy]- (CA INDEX NAME)

Absolute stereochemistry.




IT 417724-98-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of urea derivs. containing nitrogenous aromatic ring compds. as angiogenesis inhibitors for prevention or treatment of diseases)

RN 417724-98-2 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p-henoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



REFERENCE COUNT:

117 THERE ARE 117 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 22 CA COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 147:93969 CA

TITLE: Combination of anti-angiopoietin 2 human monoclonal antibody and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer

INVENTOR(S): Brown, Jeffrey Lester; Emery, Stephen Charles; Blakey, David Charles
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 88pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007068895	A1	20070621	WO 2006-GB4611	20061212
WO 2007068895	A9	20080612		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006324477	A1	20070621	AU 2006-324477	20061212
EP 1962903	A1	20080903	EP 2006-820476	20061212
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
KR 2008073766	A	20080811	KR 2008-715745	20080627
PRIORITY APPLN. INFO.:			US 2005-750551P	P 20051215
			WO 2006-GB4611	W 20061212


AB The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of a monoclonal antibody against human angiopoietin 2 (anti-Ang-2) and an antagonist of the biol. activity of VEGF-A, and/or KDR receptor, and/or FLT1, and uses of such antagonists. The nucleotide sequences and the encoded amino acid sequences of anti-Ang-2 monoclonal antibodies are disclosed.

IT 417716-92-8

RL: PAC (Pharmacological activity); BIOL (Biological study)
 (combination of anti-angiopoietin 2 human monoclonal antibody and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer)

RN 417716-92-8 CA

CN 6-Quinolinicarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 147:23734 CA
 TITLE: Anti-tumor agent for multiple myeloma
 INVENTOR(S): Kamata, Junichi
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 138pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007061127	A1	20070531	WO 2006-JP323878	20061122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1964837	A1	20080903	EP 2006-833681	20061122
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRIORITY APPLN. INFO.:			JP 2005-337772	A 20051122

US 2006-803450P P 20060530
 WO 2006-JP323878 W 20061122

OTHER SOURCE(S): MARPAT 147:23734
 GI




AB Disclosed is a pharmaceutical composition which can exert its effect with higher efficiency on a living body having at least one cell selected from the group consisting of a cell that over-expresses FGFR3, a cell that has a t(4;14) translocation and a cell that expresses a mutant FGFR3. Also disclosed is a therapeutic method for the living body. A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt can exert its effect with higher efficiency on a living body having at least one cell selected from the group consisting of a cell that over-expresses FGFR3, a cell that has a t(4;14) translocation and a cell that expresses a mutant FGFR3.

IT 417716-92-8 417717-05-6 417717-07-8
 417717-10-3 417717-15-8 417719-50-7
 417719-56-3 417719-77-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (quinolin carboxamide analogs as FGFR3 inhibitors and antitumor agents for multiple myeloma)


RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy-7-methoxy- (CA INDEX NAME)




RN 417717-05-6 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)




RN 417717-07-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 417717-10-3 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 417717-15-8 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417719-50-7 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 22 CA COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 147:23732 CA

TITLE: Anti-tumor agent for multiple myeloma

INVENTOR(S): Kamata, Junichi

PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan

SOURCE: PCT Int. Appl., 139pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007061130	A1	20070531	WO 2006-JP323881	20061122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			JP 2005-337772	A 20051122
			US 2006-803450P	P 20060530

OTHER SOURCE(S): MARPAT 147:23732

GI




AB Disclosed is a pharmaceutical composition which can exert its effect with higher efficiency on a living body having at least one cell selected from the group consisting of a cell that over-expresses FGFR3, a cell that has a t(4;14) translocation and a cell that expresses a mutant FGFR3. Also disclosed is a therapeutic method for the living body. A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt can exert its effect with higher efficiency on a living body having at least one cell selected from the group consisting of a cell that over-expresses FGFR3, a cell that has a t(4;14) translocation and a cell that expresses a mutant FGFR3.

IT 417716-92-8 417717-05-6 417717-07-8
 417717-10-3 417717-15-8 417719-50-7
 417719-56-3 417719-77-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (quinolin carboxamide analogs as FGFR3 inhibitors and antitumor agents for multiple myeloma)


RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417717-05-6 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)




RN 417717-07-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 417717-10-3 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 417717-15-8 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417719-50-7 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 22 CA COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 146:455231 CA

TITLE: Use of combination of anti-angiogenic substance and c-kit kinase inhibitor

INVENTOR(S): Yamamoto, Yuji

PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan

SOURCE: PCT Int. Appl., 102pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007052850	A1	20070510	WO 2006-JP322516	20061107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1949902	A1	20080730	EP 2006-832529	20061107
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRIORITY APPLN. INFO.:			JP 2005-322946 WO 2006-JP322516	A 20051107 W 20061107
OTHER SOURCE(S): MARPAT 146:455231				
AB Disclosed are a pharmaceutical composition having an excellent anti-tumor effect, and a therapeutic method for cancer. 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoliniccarboxamide or an analog thereof can be used in combination with a substance having a c-kit kinase-inhibiting activity to produce an excellent anti-tumor effect. For example, the effect of combination of 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoliniccarboxamide methanesulfonate and imatinib on human gastrointestinal stromal tumor cell (GIST882 cell)-bearing model mice was examined				
IT 417716-92-8, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinoliniccarboxamide 417717-05-6, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-(2-methoxyethoxy)-6-quinoliniccarboxamide 417717-07-8, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-[2-(4-morpholino)ethoxy-6-quinoliniccarboxamide 417717-10-3, 4-(3-Chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)-6-quinoliniccarboxamide 417717-15-8, 4-(3-Chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropyl]oxy-6-quinoliniccarboxamide 417719-50-7, 4-[3-Chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinoliniccarboxamide 417719-56-3, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinoliniccarboxamide 417719-77-8, 4-[3-Chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidino)propoxy]-6-quinoliniccarboxamide 857890-39-2				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (use of combination of anti-angiogenic substance and c-kit kinase inhibitor)				
RN 417716-92-8 CA				
CN 6-Quinoliniccarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p				

henoxy]-7-methoxy- (CA INDEX NAME)




RN 417717-05-6 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)




RN 417717-07-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 417717-10-3 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 417717-15-8 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417719-50-7 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 857890-39-2 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8

CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 146:455230 CA
 TITLE: Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
 INVENTOR(S): Yamamoto, Yuji
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 103pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007052849	A1	20070510	WO 2006-JP322514	20061107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,				

KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
 MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
 RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 AU 2006309551 A1 20070510 AU 2006-309551 20061107
 CA 2627598 A1 20070510 CA 2006-2627598 20061107
 KR 2008065698 A 20080714 KR 2008-713685 20080605
 PRIORITY APPLN. INFO.: JP 2005-322946 A 20051107
 WO 2006-JP322514 W 20061107

OTHER SOURCE(S): MARPAT 146:455230

AB Disclosed are a pharmaceutical composition having an excellent anti-tumor effect, and a therapeutic method for cancer. 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or an analog thereof can be used in combination with a substance having a c-kit kinase-inhibiting activity to produce an excellent anti-tumor effect. For example, the effect of combination of 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate and imatinib on human gastrointestinal stromal tumor cell (GIST882 cell)-bearing model mice was examined


IT 417716-92-8, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide 417717-05-6, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417717-07-8, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-[2-(4-morpholino)ethoxy]-6-quinolinecarboxamide 417717-10-3, 4-(3-Chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)-6-quinolinecarboxamide 417717-15-8, 4-(3-Chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropyl]oxy-6-quinolinecarboxamide 417719-50-7, 4-[3-Chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide 417719-56-3, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide 417719-77-8, 4-[3-Chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidino)propoxy]-6-quinolinecarboxamide 857890-39-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of combination of anti-angiogenic substance and c-kit kinase inhibitor)


RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417717-05-6 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)




RN 417717-07-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 417717-10-3 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 417717-15-8 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropanoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417719-50-7 CA


RN 417719-50-7 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 857890-39-2 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8

CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 146:221063 CA
 TITLE: Method for assaying anti-tumor effect of angiogenesis inhibitor
 INVENTOR(S): Uenaka, Toshimitsu; Yamamoto, Yuji; Matsui, Junji
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 147pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007015578	A1	20070208	WO 2006-JP315698	20060802
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,				

KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
 MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
 SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
 US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

EP 1925676 A1 20080528 EP 2006-768437 20060802

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, RS

PRIORITY APPLN. INFO.: JP 2005-224173 A 20050802
 JP 2006-164700 A 20060614
 WO 2006-JP315698 W 20060802


OTHER SOURCE(S): MARPAT 146:221063

AB Disclosed is a method for predicting the anti-tumor effect of an angiogenesis inhibitor. The method comprises evaluating the EGF-dependence property of an angiogenesis inhibitor with respect to proliferation and/or survival of tumor cells, and using the evaluated EGF-dependence property as a measure. The anti-tumor effect of an angiogenesis inhibitor correlates with the EGF-dependency property of the inhibitor with respect to proliferation and/or survival of tumor cells. Therefore, an angiogenesis inhibitor is capable of exerting an excellent anti-tumor effect by using it in combination with a substance having an EGF inhibitory effect.

IT 417716-92-8, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 417716-92-8D,
 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, pharmacol. allowed salt, solvate 417717-05-6
 , 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417717-07-8
 417717-10-3 417717-15-8 417719-50-7
 417719-56-3 417719-77-8 857890-39-2
 RL: ANT (Analyte); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (method for assaying anti-tumor effect of angiogenesis inhibitor by evaluating EGF-dependency)


RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p-henoxy- (CA INDEX NAME)




RN 417717-05-6 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p-henoxy-7-(2-methoxyethoxy)- (CA INDEX NAME)



RN 417717-07-8 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 417717-10-3 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 417717-15-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417719-50-7 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[([(1R,2S)-2-fluorocyclopropyl]amino)carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 857890-39-2 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 146:221062 CA
 TITLE: Method for predicting antitumor efficacy of angiogenesis inhibitor
 INVENTOR(S): Matsui, Junji; Semba, Taro
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 104pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007015569	A1	20070208	WO 2006-JP315563	20060801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1925941	A1	20080528	EP 2006-782407	20060801
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRIORITY APPLN. INFO.:			JP 2005-223440	A 20050801
			WO 2006-JP315563	W 20060801


OTHER SOURCE(S): MARPAT 146:221062
 AB A method for predicting the antitumor efficacy of an angiogenesis inhibitor is provided, which comprises measuring the number of blood vessels surrounded by pericytes in tumor, and using the measurement value as a measure for the anti-tumor effect.
 IT 417716-92-8, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 417716-92-8D,
 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, pharmacol. allowed salt, solvate 417717-05-6
 , 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417717-07-8
 417717-10-3 417717-15-8 417719-50-7

417719-56-3 417719-77-8 857890-39-2

RL: ANT (Analyte); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (method for predicting antitumor efficacy of angiogenesis inhibitor)


RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy-7-methoxy- (CA INDEX NAME)




RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy-7-methoxy- (CA INDEX NAME)




RN 417717-05-6 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy-7-(2-methoxyethoxy)- (CA INDEX NAME)



RN 417717-07-8 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 417717-10-3 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 417717-15-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417719-50-7 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[([(1R,2S)-2-fluorocyclopropyl]amino)carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 417719-56-3 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 857890-39-2 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 146:100576 CA
 TITLE: Preparation of amorphous salts of 4-[3-chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-methoxy-6-quinolinemcarboxamide as antitumor agents
 INVENTOR(S): Sakaguchi, Takahisa; Tsuruoka, Akihiko
 PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 49pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006137474	A1	20061228	WO 2006-JP312487	20060622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006260148	A1	20061228	AU 2006-260148	20060622
CA 2606719	A1	20061228	CA 2006-2606719	20060622
US 20070004773	A1	20070104	US 2006-472372	20060622
EP 1894918	A1	20080305	EP 2006-767145	20060622
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
KR 2008008374	A	20080123	KR 2007-727079	20071121
CN 101233111	A	20080730	CN 2006-80020317	20071207
PRIORITY APPLN. INFO.:			US 2005-693044P	P 20050623
			WO 2006-JP312487	W 20060622


AB This invention pertains to a method for producing amorphous salts of 4-[3-chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-methoxy-6-quinolinemcarboxamide. The title compds. are useful as antitumor agents for various cancers, such as pancreas cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, lung cancer, renal cancer, brain cancer, blood cancer, ovarian cancer, and hemangioma (no data).

IT 417716-92-8P

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of salts of 4-[3-chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-methoxy-6-quinolinecarboxamide as antitumor agents)

RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



IT 857890-31-4P 857890-33-6P 857890-35-8P

857890-37-0P 857890-39-2P 857890-41-6P


857890-45-0P 857890-47-2P 917572-43-1P

917572-44-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of salts of 4-[3-chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-methoxy-6-quinolinecarboxamide as antitumor agents)


RN 857890-31-4 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



RN 857890-33-6 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p-henoxy]-7-methoxy-, hydrobromide (1:1) (CA INDEX NAME)




RN 857890-35-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p-henoxy]-7-methoxy-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1


CRN 417716-92-8

CMF C21 H19 Cl N4 O4



CM 2


CRN 104-15-4
CMF C7 H8 O3 S



RN 857890-37-0 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, sulfate (1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2


CRN 7664-93-9
CMF H₂ O₄ S



RN 857890-39-2 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1


CRN 417716-92-8
CMF C₂₁ H₁₉ Cl N₄ O₄



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 857890-41-6 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate, hydrate (1:1:?) (CA INDEX NAME)

CM 1


CRN 417716-92-8

CMF C21 H19 Cl N4 O4



CM 2


CRN 75-75-2
CMF C H4 O3 S




RN 857890-45-0 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, acetate compd. with methanesulfonic acid (1:?:?) (CA INDEX NAME)

CM 1


CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S


CM 3

CRN 64-19-7
CMF C2 H4 O2


RN 857890-47-2 CA
 CN Ethanesulfonic acid, compd. with 4-[3-chloro-4-
 [(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-
 quinolinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 417716-92-8
CMF C21 H19 Cl N4 O4




CM 2


CRN 594-45-6
CMF C2 H6 O3 SRN 917572-43-1 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate, compd. with 1,1'-sulfinylbis[methane] (1:1:?) (CA INDEX NAME)

CM 1


CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S


CM 3

CRN 67-68-5
CMF C2 H6 O S


RN 917572-44-2 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, ethanesulfonate, compd. with 1,1'-sulfonylbis[methane] (1:1:?) (CA INDEX NAME)

CM 1


CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2

CRN 594-45-6
CMF C2 H6 O3 S

CM 3

CRN 67-68-5
CMF C2 H6 O S

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 144:324798 CA
 TITLE: Simultaneous use of sulfonamide-containing compound
 and angiogenesis inhibitor
 INVENTOR(S): Owa, Takashi; Ozawa, Yoichi; Semba, Taro
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 270 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006030941	A1	20060323	WO 2005-JP17228	20050913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2006030947	A1	20060323	WO 2005-JP17238	20050913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20060135486	A1	20060622	US 2005-226655	20050913
EP 1797877	A1	20070620	EP 2005-785820	20050913
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRIORITY APPLN. INFO.:			US 2004-609452P	P 20040913
			JP 2005-54150	A 20050228
			JP 2005-54475	A 20050228
			WO 2005-JP17238	W 20050913

OTHER SOURCE(S): MARPAT 144:324798

AB A pharmaceutical composition comprising a sulfonamide-containing compound combined

with an angiogenesis inhibitor.


IT 417716-92-8, 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 417717-05-6,
 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide 417717-07-8 417717-10-3
 417717-15-8 417719-50-7 417719-56-3
 417719-77-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sulfonamide-containing compds. and angiogenesis inhibitors for combination chemotherapy of cancer)


RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417717-05-6 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)




RN 417717-07-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 417717-10-3 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 417717-15-8 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2S)-2,3-dihydroxypropoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417719-50-7 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[[[[[1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 417719-56-3 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 144:299488 CA
 TITLE: Stable medicinal compositions of quinolinecarboxamide derivative
 INVENTOR(S): Furitsu, Hisao; Suzuki, Yasuyuki
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006030826	A1	20060323	WO 2005-JP16941	20050914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005283422	A1	20060323	AU 2005-283422	20050914
CA 2579810	A1	20060323	CA 2005-2579810	20050914
EP 1797881	A1	20070620	EP 2005-783232	20050914
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101001629	A	20070718	CN 2005-80026468	20050914
KR 2007053205	A	20070523	KR 2007-701347	20070119
IN 2007CN01571	A	20070831	IN 2007-CN1571	20070417
US 20080214604	A1	20080904	US 2008-662425	20080404
PRIORITY APPLN. INFO.:			JP 2004-272625	A 20040917
			WO 2005-JP16941	W 20050914

AB This invention relates to highly stable medicinal composition which comprises 4-(3-chloro-4-(cyclopropylamino-carbonyl)aminophenoxy)-7-methoxy-6-quinolinicarboxamide (I), salts or solvates thereof, a compound whose 5 % aqueous solution or dispersion has a pH of 8 or higher, and/or silicic acid, salts or solvates thereof. Decomposition and surface gelation of I during storage at high humidity and temperature, is prevented. For example, tablets were formulated containing I·methanesulfonate salt 24, Aerosil-200 192, mannitol 1236, Avicel PH101 720, hydroxypropyl cellulose 72, Ac-Di-Sol 120, Na stearyl fumarate 36 parts and coated with Opadry Yellow.

IT 417716-92-8P, 4-(3-Chloro-4-(cyclopropylamino-carbonyl)aminophenoxy)-7-methoxy-6-quinolinicarboxamide
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinolinicarboxamide derivative)

RN 417716-92-8 CA

CN 6-Quinolinicarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



IT 857890-39-2

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of quinolinecarboxamide derivative and stable tablets containing the same)


RN 857890-39-2 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy-7-methoxy-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2


CRN 75-75-2
CMF C H4 O3 SIT 857890-33-6 857890-35-8 857890-37-0
857890-41-6 857890-43-8 857890-45-0
857890-47-2RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of quinolinecarboxamide derivative and stable tablets
containing the
same)

RN 857890-33-6 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p
henoxy]-7-methoxy-, hydrobromide (1:1) (CA INDEX NAME)RN 857890-35-8 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p
henoxy]-7-methoxy-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2


CRN 104-15-4
CMF C7 H8 O3 S



RN 857890-37-0 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, sulfate (1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2


CRN 7664-93-9
CMF H₂ O₄ S




RN 857890-41-6 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate, hydrate (1:1:?) (CA INDEX NAME)

CM 1

CRN 417716-92-8
CMF C₂₁ H₁₉ Cl N₄ O₄




CM 2


CRN 75-75-2
CMF C H4 O3 SRN 857890-43-8 CA
CN 6-Quinoliniccarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, monomethanesulfonate, compd. with sulfonylbis[methane] (9CI) (CA INDEX NAME)

CM 1


CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S


CM 3

CRN 67-71-0
CMF C2 H6 O2 S


RN 857890-45-0 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy-7-methoxy-, acetate compd. with methanesulfonic acid (1:?:?) (CA INDEX NAME)

CM 1


CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S


CM 3

CRN 64-19-7
CMF C2 H4 O2

RN 857890-47-2 CA
 CN Ethanesulfonic acid, compd. with 4-[3-chloro-4-
 [(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-
 quinolinecarboxamide (1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2

CRN 594-45-6
CMF C2 H6 03 :




IT 857890-31-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable tablets containing quinolonecarboxamide derivative and alkalies and silicates)

RN 857890-31-4 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, hydrochloride (1:1) (CA INDEX NAME)




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 143:120562 CA
 TITLE: Crystal of salt of 4-[3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy]-7-methoxy-6-quinolinecarboxamide or solvate thereof and processes for producing these
 INVENTOR(S): Matsushima, Tomohiro; Nakamura, Taiju; Yoshizawa, Kazuhiro; Kamada, Atsushi; Ayata, Yusuke; Suzuki, Naoko; Arimoto, Itaru; Sakaguchi, Takahisa; Gotoda, Masaharu
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063713	A1	20050714	WO 2004-JP19223	20041222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2004309217	A1	20050714	AU 2004-309217	20041222
CA 2543650	A1	20050714	CA 2004-2543650	20041222
EP 1698623	A1	20060906	EP 2004-807580	20041222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1890220	A	20070103	CN 2004-80036184	20041222
BR 2004018200	A	20070417	BR 2004-18200	20041222
RU 2328489	C2	20080710	RU 2006-126977	20041222
US 20070078159	A1	20070405	US 2006-577531	20060428
MX 2006PA07256	A	20060823	MX 2006-PA7256	20060622
KR 804566	B1	20080220	KR 2006-713993	20060712
IN 2006CN02572	A	20070608	IN 2006-CN2572	20060713
NO 2006003383	A	20060925	NO 2006-3383	20060721
KR 2007107185	A	20071106	KR 2007-722490	20071001
KR 2008028511	A	20080331	KR 2008-705282	20080303
KR 839554	B1	20080620		
PRIORITY APPLN. INFO.:				
		JP 2003-430939	A 20031225	
		WO 2004-JP19223	W 20041222	
		KR 2006-713993	A3 20060712	
		KR 2007-722490	A3 20071001	
AB	Disclosed are crystals of the hydrochloride, hydrobromide, p-toluenesulfonate, sulfate, methanesulfonate, or ethanesulfonate of 4-[3-chloro-4-(cyclopropylamino-carbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide or crystals of a solvate of any of these. The crystals have improved physicochem. and pharmacokinetic properties, and suitable for use as neovascularization inhibitors for treatment of related diseases.			
IT	857890-33-6P 857890-39-2P RL: PEP (Physical, engineering or chemical process); PKT (Pharmacokinetics); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (crystal of salt of 4-[3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy]-7-methoxy-6-quinolinecarboxamide or solvate thereof as neovascularization inhibitor, and preparation thereof)			
RN	857890-33-6 CA			
CN	6-Quinolinecarboxamide, 4-[3-chloro-4-[[[cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, hydrobromide (1:1) (CA INDEX NAME)			




RN 857890-39-2 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p-henoxy-7-methoxy-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4



CM 2

CRN 75-75-2

CMF C H4 O3 S



IT 857890-43-8P 857890-45-0P

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
 (crystal of salt of 4-[3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy]-7-methoxy-6-quinolinecarboxamide or solvate thereof as neovascularization inhibitor, and preparation thereof)


RN 857890-43-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, monomethanesulfonate, compd. with sulfonylbis[methane] (9CI) (CA INDEX NAME)

CM 1

CRN 417716-92-8


CMF C21 H19 Cl N4 O4




CM 2

CRN 75-75-2

CMF C H4 O3 S




CM 3

CRN 67-71-0
CMF C2 H6 O2 S


RN 857890-45-0 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, acetate compd. with methanesulfonic acid (1:?:?) (CA INDEX NAME)

CM 1


CRN 417716-92-8
CMF C21 H19 Cl N4 O4

CM 2

CRN 75-75-2
CMF C H4 O3 S




CM 3

CRN 64-19-7
CMF C2 H4 O2IT 857890-31-4P 857890-35-8P 857890-37-0P
857890-41-6P 857890-47-2P 857890-49-4P

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (crystal of salt of 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino-phenoxy]-7-methoxy-6-quinolinecarboxamide or solvate thereof as neovascularization inhibitor, and preparation thereof)

RN 857890-31-4 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, hydrochloride (1:1) (CA INDEX NAME)




RN 857890-35-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2


CRN 104-15-4
CMF C7 H8 O3 S



RN 857890-37-0 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, sulfate (1:1) (CA INDEX NAME)


CM 1

CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2


CRN 7664-93-9
CMF H₂ O₄ S



RN 857890-41-6 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate, hydrate (1:1:?) (CA INDEX NAME)


CM 1

CRN 417716-92-8
CMF C₂₁ H₁₉ Cl N₄ O₄



CM 2


CRN 75-75-2
CMF C H4 O3 S




RN 857890-47-2 CA
CN Ethanesulfonic acid, compd. with 4-[3-chloro-4-
[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-
quinolinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 417716-92-8
CMF C21 H19 Cl N4 O4




CM 2

CRN 594-45-6
CMF C2 H6 O3 S


RN 857890-49-4 CA
 CN Ethanesulfonic acid, compd. with 4-[3-chloro-4-
 [(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-
 quinolinecarboxamide and sulfonylbis[methane] (1:1:?) (9CI) (CA INDEX
 NAME)

CM 1


CRN 417716-92-8
CMF C21 H19 Cl N4 O4



CM 2

CRN 594-45-6
CMF C2 H6 O3 S

CM 3


CRN 67-71-0
CMF C2 H6 O2 S

IT 417716-92-8P, 4-[3-Chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy]-7-methoxy-6-quinolinecarboxamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (crystal of salt of 4-[3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy]-7-methoxy-6-quinolinecarboxamide or solvate thereof as neovascularization inhibitor, and preparation thereof)

RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p

heoxy]-7-methoxy- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 19 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 142:481959 CA
 TITLE: Preparation of urea moiety-containing quinolinecarboxamide derivatives
 INVENTOR(S): Naito, Toshihiko; Yoshizawa, Kazuhiro
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044788	A1	20050519	WO 2004-JP16526	20041108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1683785	A1	20060726	EP 2004-818213	20041108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				

CN 1878751	A 20061213	CN 2004-80033071	20041108
US 20070037849	A1 20070215	US 2006-577308	20060428
IN 2006CN02045	A 20070601	IN 2006-CN2045	20060609
PRIORITY APPLN. INFO.:		JP 2003-381249	A 20031111
		WO 2004-JP16526	W 20041108

OTHER SOURCE(S): CASREACT 142:481959; MARPAT 142:481959

GI



AB The title compds. I [wherein R1 is hydrogen, C1-6 alkyl, or C3-8 cycloalkyl; and R2 is hydrogen or methoxy] are prepared by reaction of 4-amino-3-chlorophenol with aryl chloroformate, followed by reaction with an amine and reaction of the resulting urea derivative with a chloroquinoline derivative I are useful in the treatment of diseases accompanied by abnormal proliferation of angiogenesis (no data). Thus, reaction of 4-amino-3-chlorophenol with Ph chloroformate, followed by reaction with cyclopropylamine and reaction of the resulting urea derivative with 7-methoxy-4-chloroquinoline-6-carboxamide, gave 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.


IT 417716-92-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amination of aryl chloroformate or amination of aryl N-hydroxyphenylcarbamate)

RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 141:427993 CA
 TITLE: Polymorphous crystal of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and method for preparation thereof
 INVENTOR(S): Arimoto, Itaru; Yoshizawa, Kazuhiro; Kamada, Atsushi
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004101526	A1	20041125	WO 2004-JP5788	20040422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070117842	A1	20070524	US 2006-553927	20060630
PRIORITY APPLN. INFO.:			US 2003-464674P	P 20030422
			WO 2004-JP5788	W 20040422

AB Disclosed are a polymorphous crystal (A) of 4-(3-chloro-4-


(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (I) having a diffraction peak at a diffraction angle ($2\theta \pm 0.2^\circ$) of 15.75° in the powder X-ray diffractometry; and a polymorphous crystal (B) of I having a diffraction peak at a diffraction angle ($2\theta \pm 0.2^\circ$) of 21.75° in the powder X-ray diffractometry.

IT 417716-92-8P

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide polymorphous crystals)

RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 22 CA COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 141:289013 CA

TITLE: c-Kit kinase inhibitor

INVENTOR(S): Yamamoto, Yuji; Watanabe, Tatsuo; Okada, Masayuki; Tsuruoka, Akihiko

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080462	A1	20040923	WO 2004-JP3087	20040310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG

US 20040253205 A1 20041216 US 2004-797903 20040310


EP 1604665 A1 20051214 EP 2004-719054 20040310

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.: JP 2003-62823 A 20030310
 JP 2003-302803 A 20030827
 WO 2004-JP3087 W 20040310

OTHER SOURCE(S): MARPAT 141:289013

GI




AB It is found out that a compound represented by the following general formula I (R1 = Me, etc.; R2 = cyano, etc.; R3 = H, etc.; and R4 = H, etc.) shows a potent c-Kit kinase inhibitory activity and suppresses the proliferation of cancer cells activated by c-Kit kinase both in vitro and in vivo. Thus, a novel anticancer agent showing a c-Kit kinase inhibitory activity is found out.

IT 417716-92-8, 4-(3-Chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (c-Kit kinase inhibitor)

RN 417716-92-8 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 22 CA COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 136:340689 CA
 TITLE: Preparation of urea derivatives containing nitrogenous aromatic ring compounds as inhibitors of angiogenesis
 INVENTOR(S): Funahashi, Yasuhiro; Tsuruoka, Akihiko; Matsukura, Masayuki; Haneda, Toru; Fukuda, Yoshio; Kamata, Junichi; Takahashi, Keiko; Matsushima, Tomohiro; Miyazaki, Kazuki; Nomoto, Kenichi; Watanabe, Tatsuo; Obaishi, Hiroshi; Yamaguchi, Atsumi; Suzuki, Sachie; Nakamura, Katsuji; Mimura, Fusayo; Yamamoto, Yuji; Matsui, Junji; Matsui, Kenji; Yoshioka, Takako; Suzuki, Yasuyuki; Arimoto, Itaru
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 699 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032872	A1	20020425	WO 2001-JP9221	20011019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

CA 2426461	A1	20020425	CA 2001-2426461	20011019
AU 2001095986	A	20020429	AU 2001-95986	20011019
HU 2003002603	A2	20031128	HU 2003-2603	20011019
CN 1478078	A	20040225	CN 2001-819710	20011019
EP 1415987	A1	20040506	EP 2001-976786	20011019
EP 1415987	B1	20070228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
EP 1506962	A2	20050216	EP 2004-25700	20011019
EP 1506962	A3	20050302		
EP 1506962	B1	20080702		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
NZ 525324	A	20050324	NZ 2001-525324	20011019
JP 3712393	B2	20051102	JP 2002-536056	20011019
RU 2264389	C2	20051120	RU 2003-114740	20011019
AT 355275	T	20060315	AT 2001-976786	20011019
AU 2001295986	B2	20060817	AU 2001-295986	20011019
EP 1777218	A1	20070425	EP 2006-23078	20011019
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
CN 101024627	A	20070829	CN 2007-10007096	20011019
CN 101029022	A	20070905	CN 2007-10007097	20011019
ES 2282299	T3	20071016	ES 2001-976786	20011019
AT 399766	T	20080715	AT 2004-25700	20011019
NO 2003001731	A	20030619	NO 2003-1731	20030414
MX 2003PA03362	A	20030801	MX 2003-PA3362	20030415
US 7253286	B2	20070807	US 2003-420466	20030418
US 20040053908	A1	20040318		
ZA 2003003567	A	20040810	ZA 2003-3567	20030508
JP 2005272474	A	20051006	JP 2005-124034	20050421
US 20060247259	A1	20061102	US 2005-293785	20051202
US 20060160832	A1	20060720	US 2006-347749	20060203
AU 2006203099	A1	20060810	AU 2006-203099	20060719
AU 2006236039	A1	20061207	AU 2006-236039	20061116
AU 2006236039	B2	20080522		
NO 2007004657	A	20030619	NO 2007-4657	20070912
PRIORITY APPLN. INFO.:				
		JP 2000-320420	A	20001020
		JP 2000-386195	A	20001220
		JP 2001-46685	A	20010222
		AU 2001-295986	A3	20011019
		AU 2001-95986	TO	20011019
		CN 2001-819710	A3	20011019
		EP 2001-976786	A3	20011019
		JP 2002-536056	A3	20011019
		WO 2001-JP9221	W	20011019
		US 2003-420466	A3	20030418
		US 2005-293785	A1	20051202

OTHER SOURCE(S): MARPAT 136:340689
GI




AB N-aryl or N-heteroarylurea derivs. represented by the general formula Ag-Xg-Yg-Tg1 or salts thereof, or hydrates of both [wherein Ag = (un)substituted C6-14 aryl or 5- to 14-membered heterocyclic group; Xg = single bond, O, S, C1-6 alkylene, SO, SO2, (un)substituted NH; Yg = (un)substituted C6-14 aryl, 5- to 14-membered heterocyclic group, C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl-C1-6 alkyl, 5- to 14-membered heteroaryl-C1-6 alkyl, (CH2)gSO2 (g = 1-8), (CH2)fACh:CH(CH2)fb (fa, fb = 0, 1, 2, 3), etc.; and Tg1 = a group of the general formula -Eg-CO-NRg1(Zg) or Q; wherein Eg = a single bond, (un)substituted NH; Rg1 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 aliphatic hydrocarbyl, etc.; Zg = C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl, etc.; Zg1, Zg2 = (a) a single bond, (b) C1-6 alkylene optionally having ≥ 1 atoms selected from O, S, and N in the middle or the terminus of the chain and optionally substituted with oxo, (c) (un)substituted C2-6 alkenyl] are prepared. These compds. are also inhibitors of vascular endothelial growth factor receptor kinase (VEGFR2 kinase) and are useful as antitumor agents against hemangioma, pancreatic cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, lung cancer, brain tumor, leukemia, or ovarian cancer, as cancer metastasis inhibitors, and for the treatment of retina neovascularization, diabetic retinopathy, atherosclerosis, or inflammatory diseases such as osteoarthritis, rheumatoid arthritis, psoriasis, or delayed hypersensitivity. Thus, to a solution of 334 mg 4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenylamine in 4 mL DMF were added 0.066 mL pyridine and 0.102 mL Ph chlorocarbonate and stirred at room temperature for 2.5 h to give 330 mg N-[4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea which (260 mg) was hydrogenolyzed over platinum oxide in ethanol overnight to give 160 mg N-[4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea (I). I showed IC50 of 0.02 nM for inhibiting the vascular endothelial growth factor (VEGF)-stimulated sandwich tube formation in vascular endothelial cell.

IT 417717-12-5P 417717-13-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of urea derivs. containing nitrogenous aromatic ring compds. as angiogenesis inhibitors for prevention or treatment of diseases)

RN 417717-12-5 CA

CN 6-Quinolinicarboxamide, 4-[3-chloro-4-[[cyclopropylamino]carbonyl]amino]phenoxy]-7-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417717-13-6 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



IT 417716-92-8P 417717-03-4P 417717-05-6P

417717-06-7P 417717-07-8P 417717-08-9P

417717-09-0P 417717-10-3P 417717-11-4P

417717-14-7P 417717-15-8P 417717-16-9P

417717-17-0P 417717-18-1P 417717-19-2P

417719-50-7P 417719-56-3P 417719-57-4P


417719-77-8P 417720-06-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of urea derivs. containing nitrogenous aromatic ring compds. as angiogenesis inhibitors for prevention or treatment of diseases)

RN 417716-92-8 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy- (CA INDEX NAME)




RN 417717-03-4 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(phenylmethoxy)- (CA INDEX NAME)




RN 417717-05-6 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-methoxyethoxy)- (CA INDEX NAME)



RN 417717-06-7 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)




RN 417717-07-8 CA
CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 417717-08-9 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 417717-09-0 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 417717-10-3 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 417717-11-4 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(3-hydroxypropoxy)- (CA INDEX NAME)



RN 417717-14-7 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p-henoxy]-7-[(2R)-2,3-dihydroxypropoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 417717-15-8 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]p-henoxy]-7-[(2S)-2,3-dihydroxypropoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 417717-16-9 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(1,3-dioxolan-2-ylmethoxy)- (CA INDEX NAME)




RN 417717-17-0 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[3-(diethylamino)propoxy]- (CA INDEX NAME)



RN 417717-18-1 CA
 CN 1-Piperidinecarboxylic acid, 4-[[[6-(aminocarbonyl)-4-[3-chloro-4-
 [(cyclopropylamino)carbonyl]amino]phenoxy]-7-quinolinyloxy]methyl]-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 417717-19-2 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 417719-50-7 CA


CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]amino]phenoxy]-7-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 417719-56-3 CA

CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(2-ethoxyethoxy)- (CA INDEX NAME)




RN 417719-57-4 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(cyclopropylmethoxy)- (CA INDEX NAME)



RN 417719-77-8 CA
 CN 6-Quinolinecarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-2-hydroxy-3-(1-pyrrolidinyl)propoxy)- (CA INDEX NAME)


Absolute stereochemistry.



RN 417720-06-0 CA

CN 6-Quinolincarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-[(2R)-3-(diethylamino)-2-hydroxypropoxy]- (CA INDEX NAME)

Absolute stereochemistry.




IT 417724-98-2P, 4-(3-Chloro-4-((cyclopropylamino)carbonyl)amino)phenoxy)-7-((4-piperidyl)methoxy)-6-quinolincarboxamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of urea derivs. containing nitrogenous aromatic ring compds. as angiogenesis inhibitors for prevention or treatment of diseases)

RN 417724-98-2 CA

CN 6-Quinolincarboxamide, 4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

⇒

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 14:22:26 ON 10 SEP 2008